Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals sees a sudden 2.4% stake rise by Vanguard and State Street, sparking takeover buzz and UBS‑boosted valuations—why the move matters.

Avadel Pharmaceuticals sees heavy institutional buying from BlackRock, TIG Advisors and others, highlighting confidence in its niche urology, CNS and sleep drug portfolio.

Avadel Pharmaceuticals PLC shares hit $21.50 as shareholders approve a strategic acquisition, with major investors like Vanguard and State Street filing 1%+ stake disclosures under the Irish Takeover Panel Act, signaling a potential market shift for…

Avadel Pharmaceuticals sees institutional surge—BlackRock, Vanguard, and more stake up to 6.72%—sparking takeover‑panel filings and hinting at a possible strategic move that could unlock hidden value.

Avadel Pharmaceuticals faces a surge of institutional buying amid a steeply negative P/E, raising questions about hidden value or speculative risk.

Avadel Pharmaceuticals faces a $2.1 bn Alkermes takeover and heavy institutional activity—learn how this could reshape its valuation and volatility.

Avadel Pharmaceuticals sees a surge of institutional interest—BlackRock, Citadel, Vanguard, and others stake 13‑15% as Lundbeck and Alkermes battle over its sleep‑disorder portfolio, potentially reshaping its $2.25 billion valuation.

Avadel Pharmaceuticals: BlackRock, Vanguard and Wells Fargo lift interest as institutional stakes rise, analyst targets hit $20, and the stock nears a 52‑week high—what does this mean for investors?

Avadel Pharmaceuticals sees a surge of institutional buying, with 14 funds reporting stakes in a volatile specialty‑drug stock that’s still loss‑making but near a 52‑week high. Read why big players may signal a turning point for this $1.84 billion c…

Avadel Pharmaceuticals, a specialty pharmaceutical company, is facing significant financial challenges, including a negative price-to-earnings ratio and stock price volatility, which raises concerns about its financial stability and investor confide…